Composite lymphomas have rarely been reported in Hodgkin's disease (HD), except in the lymphocyte predominance sub-type, and immunohistochemical investigations have been performed in only few cases. We describe the histological and immunophenotypical findings in a case of composite nodular sclerosing HD and high-grade, large cell non-Hodgkin's lymphoma (NHL). In our case HD and NHL cells displayed striking morphological and immunophenotypical divergence, suggesting a lack of correlation between the two neoplasms.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/BF01611185 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Modified Endothelial Activation and Stress Index: A New Predictor for Survival Outcomes in Classical Hodgkin Lymphoma Treated with Doxorubicin-Bleomycin-Vinblastine-Dacarbazine-Based Therapy.
Diagnostics (Basel)
January 2025
Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Bursa Uludag University, Bursa 16059, Turkey.
Although the cure rates of classical Hodgkin Lymphoma (cHL) are as high as 90% using the current treatment protocols, the prognosis is poor for primary refractory patients. Thus, a biomarker that can predict patients with early progression at the time of diagnosis is an unmet clinical need. Endothelial activation and stress index (EASIX) and its variant modified EASIX (mEASIX) is a scoring system currently used for the prediction of prognosis in hematologic malignancies.
View Article and Find Full Text PDFA Novel Case of Pulmonary Sclerosing Diffuse PEComatosis With Neuroendocrine Cell Hyperplasia.
Am J Surg Pathol
January 2025
Departments of Pathology.
Proliferations of neoplastic perivascular epithelioid cells (PECs) may occur within the lung and extrathoracic sites. The term "PEComatosis" is applied to multiple or diffuse microscopic proliferations of neoplastic PECs. Pulmonary diffuse PEComatosis is extremely rare, with only one case documented in the literature to date.
View Article and Find Full Text PDFA case of sclerosing angiomatoid nodular transformation with central calcification.
Radiol Case Rep
March 2025
Department of Radiology, Mie University, 2-174 Edobashi, Tsu, 514-8507 Mie, Japan.
Sclerosing angiomatoid nodular transformation (SANT) is a rare benign vascular disease and mostly discovered incidentally in asymptomatic patients. Since SANT grows over time and it is often difficult to rule out malignancy on imaging, splenectomy is frequently the treatment of choice. Image findings of SANT have been reported as low signal intensity on T2-weighted magnetic resonance (MR) images and a characteristic enhancement pattern on dynamic contrast-enhanced computed tomography (CT) and MR images.
View Article and Find Full Text PDFSclerosing angiomatoid nodular transformation (SANT) of the spleen: a case report.
Oxf Med Case Reports
December 2024
Department of Radiation Oncology, Bank of Cyprus Oncology Center, 32 Acropoleos Avenue, Nicosia 2011, Cyprus.
SANT is a rare, non-lymphoid, benign entity, originating from the red pulp of the spleen. It is characterized by the presence of vascular nodules surrounded by a stroma of collagen fibers. It was introduced as a distinct disease entity by Martel et al in 2004, after the histopathological examination of 25 cases.
View Article and Find Full Text PDFA rare case of sclerosing angiomatoid nodular transformation of spleen: A case report.
Int J Surg Case Rep
January 2025
Jimma University, Institute of Health, Faculty of Medical Sciences, Department of Biomedical Sciences, Jimma, Ethiopia. Electronic address:
Introduction And Importance: Sclerosing angiomatoid nodular transformation of the spleen is a rare benign vascular lesion arising from red pulp of spleen with unknown etiopathogenesis. It is a non-neoplastic condition that affects the spleen only; not described in other sites except one case reported in adrenal gland. Epidemiologically it has slight female predilection.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!